Peptris Technologies

What Peptris Technologies does

Peptris Technologies is a Bengaluru-based, AI-powered preclinical drug discovery company founded in 2019 that uses proprietary artificial intelligence to design novel therapeutic molecules. The company operates a virtual model, focusing on AI-driven discovery in-house while outsourcing wet lab operations to Contract Research Organizations and biotech partners. Its proprietary platform integrates unsupervised learning with generative AI, leveraging neural network architectures drawn from natural language processing, large language models, and image processing to navigate chemical space. The platform is anchored on a foundational unsupervised learning algorithm and a large language model built on a novel, proprietary molecule language syntax, enabling the de novo design of Novel Chemical Entities (NCEs), the repurposing of approved drugs, and the rescue of clinical-stage candidates that have already passed Phase I safety evaluation.

The pipeline includes PEPR-124 (RT-001), a Phase 2-ready repurposed candidate for Duchenne Muscular Dystrophy that received USFDA Orphan Drug Designation and was exclusively licensed to Revio Therapeutics in March 2025, plus additional NCE programs (PEPR111 in lead optimization, PEPR112 in lead stage) and repurposing candidates (PEPR401, PEPRX101 in in-vitro validation) spanning oncology, inflammation, rare diseases, and women's health. Peptris monetizes through a B2B model, generating revenue via upfront licensing fees, development milestone payments, and royalties on licensed assets, with partnerships spanning pharmaceutical companies, biotechnology firms, academic institutions, and rare disease organizations. Pricing is custom and not publicly disclosed, reflecting negotiated enterprise deals.

Headquartered at the Center for Cellular and Molecular Platforms (C-CAMP) in Bengaluru, Peptris operates with a lean cross-functional team (founding executives in CEO, CTO, CSO, and Chief Data Scientist roles, plus a small core team and advisors) and is actively hiring. The company is building business development capabilities in the United States and Europe to support global licensing expansion. As of February 2026, cumulative funding stands at approximately $8.7 million, with the ₹70 crore ($7.7M) Series A co-led by IAN Alpha Fund and Speciale Invest earmarked for advancing programs toward clinical readiness, pipeline expansion, and team buildout over 24 months.

Name

Peptris Technologies

Legal name

Peptris Technologies Pvt. Ltd.

Website

https://peptris.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Peptris Technologies is a Bengaluru-based AI-powered preclinical drug discovery company founded in 2019 that uses proprietary generative AI and unsupervised learning to design novel molecules, repurpose approved drugs, and license candidates to pharmaceutical and biotechnology partners via milestone-based deals.

Ownership category

akta.pro rank

Product category

AI Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)

Keywords

• AI drug discovery
• Generative molecule design
• Preclinical drug discovery
• Drug repurposing
• Novel chemical entities

Headquarters

HQ city

Bengaluru

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Licensing Deals: Revenue generated from licensing proprietary AI-discovered molecules and drug candidates to pharmaceutical and biotechnology companies.
2. Milestone Payments: Payments tied to achievement of specific development milestones in drug discovery programs.
3. Royalties: Ongoing royalties from licensed assets that reach clinical development and commercialization.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Peptris Technologies operates an AI-powered preclinical drug discovery platform that uses proprietary unsupervised learning and generative AI to design novel molecules and predict drug development parameters. The company discovers Novel Chemical Entities (NCEs), repurposes approved drugs, and rescues clinical-stage molecules, then monetizes the resulting drug candidates through licensing deals, milestone payments, and royalties with pharmaceutical, biotechnology, and rare disease partners.

Product overview

Peptris operates an AI-powered preclinical drug discovery platform that generates novel molecules and predicts drug development parameters. The platform integrates unsupervised learning and generative AI to design optimized drug candidates, significantly reducing wet lab testing requirements. The company runs a virtual model, partnering with CROs and biotech firms for wet lab work while retaining AI-driven discovery in-house. Revenue derives from licensing deals, milestone payments, and royalties. The pipeline includes Novel Chemical Entities (NCEs) such as PEPR111 and PEPR112, alongside repurposed drugs including PEPR124 (RT-001), India's first AI-discovered drug candidate for Duchenne Muscular Dystrophy, which achieved Orphan Drug Designation from USFDA and was licensed to Revio Therapeutics in March 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• PEPR-124 (RT-001) India's first AI-discovered drug candidate, a repurposed, Phase 2-ready molecule targeting Duchenne Muscular Dystrophy (DMD). Granted Orphan Drug Designation by USFDA, with a mutation-agnostic therapeutic approach and strong safety profile. Licensed exclusively to Revio Therapeutics in March 2025.
• PEPR111 Novel Chemical Entity (NCE) in Lead Optimization stage targeting Oncology, Inflammation, and Rare Diseases. Generated using Peptris' proprietary AI platform and validated in in vitro and in vivo disease models.
• PEPR112 Novel Chemical Entity in lead stage targeting Oncology, Inflammation, or Rare Diseases, discovered and validated using Peptris' proprietary AI models.
• PEPR401 Repurposed drug candidate in in-vitro validation stage within Peptris' drug repurposing pipeline, targeting Oncology indications.
• PEPRX101 Repurposed drug candidate in in-vitro validation stage within Peptris' drug repurposing pipeline, targeting Inflammation indications.

Quantifiable outcome

• AI capable of cutting early-stage development costs by 50-60% compared to traditional methods
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Three partnerships are on record, tiered flagship, core and minor.

• Revio TherapeuticsflagshipOEM/ Whitelabel/ Licensing PartnerExclusive licensing agreement for PEPR-124 (RT-001), India's first AI-discovered drug candidate for Duchenne Muscular Dystrophy. PEPR-124 is a Phase 2-ready repurposed candidate granted Orphan Drug Designation by USFDA with mutation-agnostic therapeutic approach and strong safety profile.
• CROs and Biotech PartnerscoreStrategic or Co-development PartnerPartnerships with Contract Research Organizations for wet lab work. The company operates virtually, outsourcing wet lab operations while focusing on AI-driven discovery.
• Academic InstitutionsminorStrategic or Co-development PartnerPartnerships with academic institutions for research collaboration in drug discovery.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Insilico Medicine: AI-driven drug discovery company using generative chemistry and deep learning to identify novel targets and molecules; directly comparable to Peptris in applying generative AI to small molecule design and pipeline advancement, but at significantly larger scale.
• Exscientia: Pioneer in AI-driven small molecule design using generative models and active learning; closely comparable to Peptris in offering generative AI molecule design with pharma partnerships, though now operating at substantially larger scale and clinical maturity.
• Atomwise: AI company using structure-based design and virtual screening for small molecule discovery; directly comparable to Peptris in applying AI to virtual library screening and novel molecule generation for pharma and biotech partners.
• BenevolentAI: AI drug discovery company combining knowledge graphs and machine learning for target identification and molecule design; comparable to Peptris in offering AI-driven discovery partnerships with pharma, though at later clinical stage.
• Iambic Therapeutics: AI-driven drug discovery company combining physics-based modeling with generative AI to design novel therapeutics; directly comparable to Peptris in using foundation models and generative chemistry for preclinical small molecule programs.

Broad incumbents

• Recursion Pharmaceuticals: Publicly listed AI drug discovery platform combining high-throughput wet-lab experimentation with machine learning; comparable to Peptris in pursuing AI-enabled discovery across multiple therapeutic areas but at much greater scale and with broader infrastructure.
• Schrödinger: Computational chemistry and materials science platform with pharma discovery services; comparable to Peptris in applying physics-based modeling and ML to drug discovery, but operates a broader platform spanning software licensing and internal programs.
• Isomorphic Labs: Alphabet-owned AI drug discovery company building on DeepMind's protein structure prediction work; comparable to Peptris in applying frontier AI to drug design, but with vastly greater resources and a focus on larger pharma partnerships.

Emerging players

• Cradle Bio: AI company specializing in protein design and engineering using generative models; comparable to Peptris in applying generative AI to biomolecule design but focused on biologics rather than small molecules.
• Generate Biomedicines: Generative biology company using AI to design novel protein therapeutics; comparable to Peptris in applying generative AI to drug discovery but focused on biologics rather than small molecules, with a larger funding base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/peptris-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Peptris Technologies